Annual Net Income
-$440.24 M
+$690.91 M+61.08%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual net profit is currently -$440.24 million, with the most recent change of +$690.91 million (+61.08%) on 31 December 2023. During the last 3 years, it has risen by +$418.04 million (+48.71%). ALNY annual net income is now -10544.15% below its all-time high of -$4.14 million, reached on 31 December 2002.ALNY Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$111.57 M
-$94.68 M-560.61%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly net profit is currently -$111.57 million, with the most recent change of -$94.68 million (-560.61%) on 30 September 2024. Over the past year, it has dropped by -$259.32 million (-175.51%). ALNY quarterly net income is now -175.51% below its all-time high of $147.75 million, reached on 30 September 2023.ALNY Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$332.26 M
-$259.32 M-355.52%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM net profit is currently -$332.26 million, with the most recent change of -$259.32 million (-355.52%) on 30 September 2024. Over the past year, it has increased by +$177.60 million (+34.83%). ALNY TTM net income is now -15346.95% below its all-time high of -$2.15 million, reached on 31 March 2003.ALNY TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +61.1% | -175.5% | +34.8% |
| 3 y3 years | +48.7% | +45.5% | +60.4% |
| 5 y5 years | +42.2% | +46.5% | +59.5% |
ALNY Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +61.1% | -175.5% | +72.5% | -355.5% | +71.9% |
| 5 y | 5 years | at high | +61.1% | -175.5% | +72.5% | -355.5% | +71.9% |
| alltime | all time | <-9999.0% | +61.1% | -175.5% | +72.5% | <-9999.0% | +71.9% |
Alnylam Pharmaceuticals Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$111.57 M(+560.6%) | -$332.26 M(+355.5%) |
| June 2024 | - | -$16.89 M(-74.4%) | -$72.94 M(-78.0%) |
| Mar 2024 | - | -$65.94 M(-52.2%) | -$332.08 M(-24.6%) |
| Dec 2023 | -$440.24 M(-61.1%) | -$137.87 M(-193.3%) | -$440.24 M(-13.7%) |
| Sept 2023 | - | $147.75 M(-153.5%) | -$509.87 M(-52.1%) |
| June 2023 | - | -$276.02 M(+58.5%) | -$1.06 B(-0.1%) |
| Mar 2023 | - | -$174.10 M(-16.1%) | -$1.06 B(-5.9%) |
| Dec 2022 | -$1.13 B(+32.6%) | -$207.49 M(-48.9%) | -$1.13 B(-4.3%) |
| Sept 2022 | - | -$405.92 M(+46.3%) | -$1.18 B(+20.5%) |
| June 2022 | - | -$277.40 M(+15.4%) | -$980.72 M(+9.8%) |
| Mar 2022 | - | -$240.34 M(-7.0%) | -$892.87 M(+4.7%) |
| Dec 2021 | -$852.82 M(-0.6%) | -$258.46 M(+26.4%) | -$852.82 M(+1.8%) |
| Sept 2021 | - | -$204.51 M(+7.9%) | -$837.90 M(-5.5%) |
| June 2021 | - | -$189.56 M(-5.4%) | -$886.68 M(+1.2%) |
| Mar 2021 | - | -$200.29 M(-17.8%) | -$876.35 M(+2.1%) |
| Dec 2020 | -$858.28 M(-3.1%) | -$243.54 M(-3.8%) | -$858.28 M(-3.7%) |
| Sept 2020 | - | -$253.29 M(+41.3%) | -$890.93 M(+5.3%) |
| June 2020 | - | -$179.23 M(-1.6%) | -$846.17 M(-4.5%) |
| Mar 2020 | - | -$182.22 M(-34.0%) | -$886.42 M(+0.0%) |
| Dec 2019 | -$886.12 M(+16.4%) | -$276.19 M(+32.4%) | -$886.12 M(+7.9%) |
| Sept 2019 | - | -$208.53 M(-5.0%) | -$821.37 M(-4.3%) |
| June 2019 | - | -$219.48 M(+20.7%) | -$858.12 M(+7.0%) |
| Mar 2019 | - | -$181.91 M(-14.0%) | -$802.20 M(+5.3%) |
| Dec 2018 | -$761.50 M(+55.1%) | -$211.44 M(-13.8%) | -$761.50 M(+10.0%) |
| Sept 2018 | - | -$245.28 M(+50.0%) | -$692.28 M(+21.5%) |
| June 2018 | - | -$163.56 M(+15.8%) | -$569.94 M(+8.6%) |
| Mar 2018 | - | -$141.21 M(-0.7%) | -$524.80 M(+6.9%) |
| Dec 2017 | -$490.87 M(+19.7%) | -$142.23 M(+15.7%) | -$490.87 M(+6.3%) |
| Sept 2017 | - | -$122.94 M(+3.8%) | -$461.58 M(+4.3%) |
| June 2017 | - | -$118.42 M(+10.4%) | -$442.71 M(+6.8%) |
| Mar 2017 | - | -$107.29 M(-5.0%) | -$414.42 M(+1.1%) |
| Dec 2016 | -$410.11 M(+41.4%) | -$112.93 M(+8.5%) | -$410.11 M(+5.7%) |
| Sept 2016 | - | -$104.07 M(+15.5%) | -$387.89 M(+7.6%) |
| June 2016 | - | -$90.13 M(-12.5%) | -$360.62 M(+5.4%) |
| Mar 2016 | - | -$102.97 M(+13.5%) | -$342.27 M(+18.0%) |
| Dec 2015 | -$290.07 M(-19.5%) | -$90.72 M(+18.1%) | -$290.07 M(+31.4%) |
| Sept 2015 | - | -$76.79 M(+7.0%) | -$220.74 M(+17.5%) |
| June 2015 | - | -$71.78 M(+41.4%) | -$187.94 M(+17.3%) |
| Mar 2015 | - | -$50.78 M(+137.4%) | -$160.23 M(-55.5%) |
| Dec 2014 | -$360.39 M(+303.9%) | -$21.39 M(-51.4%) | -$360.39 M(-3.0%) |
| Sept 2014 | - | -$43.99 M(-0.2%) | -$371.36 M(+4.0%) |
| June 2014 | - | -$44.07 M(-82.4%) | -$357.06 M(+7.8%) |
| Mar 2014 | - | -$250.94 M(+675.5%) | -$331.15 M(+271.1%) |
| Dec 2013 | -$89.22 M | -$32.36 M(+9.0%) | -$89.22 M(-25.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | -$29.69 M(+63.4%) | -$119.06 M(+9.4%) |
| June 2013 | - | -$18.17 M(+101.6%) | -$108.87 M(+5.0%) |
| Mar 2013 | - | -$9.01 M(-85.5%) | -$103.66 M(-2.2%) |
| Dec 2012 | -$106.01 M(+83.9%) | -$62.19 M(+218.9%) | -$106.01 M(+82.4%) |
| Sept 2012 | - | -$19.50 M(+50.5%) | -$58.13 M(+12.1%) |
| June 2012 | - | -$12.96 M(+14.0%) | -$51.86 M(-1.6%) |
| Mar 2012 | - | -$11.37 M(-20.5%) | -$52.73 M(-8.5%) |
| Dec 2011 | -$57.65 M(+32.5%) | -$14.30 M(+8.1%) | -$57.65 M(+14.7%) |
| Sept 2011 | - | -$13.24 M(-4.2%) | -$50.28 M(+7.7%) |
| June 2011 | - | -$13.82 M(-15.1%) | -$46.67 M(-1.7%) |
| Mar 2011 | - | -$16.29 M(+135.0%) | -$47.48 M(+9.1%) |
| Dec 2010 | -$43.52 M(-8.6%) | -$6.93 M(-28.0%) | -$43.52 M(-1.9%) |
| Sept 2010 | - | -$9.63 M(-34.2%) | -$44.38 M(+1.0%) |
| June 2010 | - | -$14.63 M(+18.7%) | -$43.95 M(-15.5%) |
| Mar 2010 | - | -$12.32 M(+58.2%) | -$52.02 M(+9.3%) |
| Dec 2009 | -$47.59 M(+81.3%) | -$7.79 M(-15.4%) | -$47.59 M(-3.3%) |
| Sept 2009 | - | -$9.21 M(-59.4%) | -$49.19 M(+14.8%) |
| June 2009 | - | -$22.70 M(+187.8%) | -$42.84 M(+30.2%) |
| Mar 2009 | - | -$7.89 M(-16.0%) | -$32.90 M(+25.3%) |
| Dec 2008 | -$26.25 M(-69.3%) | -$9.39 M(+228.6%) | -$26.25 M(+72.7%) |
| Sept 2008 | - | -$2.86 M(-77.6%) | -$15.20 M(-76.7%) |
| June 2008 | - | -$12.76 M(+929.9%) | -$65.13 M(+0.1%) |
| Mar 2008 | - | -$1.24 M(-174.5%) | -$65.06 M(-23.9%) |
| Dec 2007 | -$85.47 M(+147.0%) | $1.66 M(-103.1%) | -$85.47 M(-10.6%) |
| Sept 2007 | - | -$52.79 M(+316.0%) | -$95.57 M(+90.5%) |
| June 2007 | - | -$12.69 M(-41.4%) | -$50.17 M(+5.9%) |
| Mar 2007 | - | -$21.64 M(+156.5%) | -$47.39 M(+36.9%) |
| Dec 2006 | -$34.61 M(-19.4%) | -$8.44 M(+14.0%) | -$34.61 M(-14.9%) |
| Sept 2006 | - | -$7.40 M(-25.3%) | -$40.66 M(-7.5%) |
| June 2006 | - | -$9.91 M(+11.9%) | -$43.94 M(-2.7%) |
| Mar 2006 | - | -$8.86 M(-38.9%) | -$45.17 M(+5.3%) |
| Dec 2005 | -$42.91 M(+31.4%) | -$14.49 M(+35.7%) | -$42.91 M(+25.8%) |
| Sept 2005 | - | -$10.68 M(-4.2%) | -$34.12 M(+14.3%) |
| June 2005 | - | -$11.14 M(+68.9%) | -$29.86 M(+16.3%) |
| Mar 2005 | - | -$6.60 M(+15.8%) | -$25.67 M(-21.4%) |
| Dec 2004 | -$32.65 M(+30.4%) | -$5.70 M(-11.2%) | -$32.65 M(-1.7%) |
| Sept 2004 | - | -$6.42 M(-7.8%) | -$33.21 M(+0.5%) |
| June 2004 | - | -$6.96 M(-48.8%) | -$33.05 M(+12.7%) |
| Mar 2004 | - | -$13.58 M(+117.0%) | -$29.34 M(+63.8%) |
| Dec 2003 | -$25.03 M(+505.2%) | -$6.26 M(0.0%) | -$17.91 M(+53.7%) |
| Sept 2003 | - | -$6.26 M(+92.9%) | -$11.65 M(+116.0%) |
| June 2003 | - | -$3.24 M(+50.8%) | -$5.39 M(+150.8%) |
| Mar 2003 | - | -$2.15 M | -$2.15 M |
| Dec 2002 | -$4.14 M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual net profit?
- What is the all time high annual net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual net income year-on-year change?
- What is Alnylam Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly net income year-on-year change?
- What is Alnylam Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM net income year-on-year change?
What is Alnylam Pharmaceuticals annual net profit?
The current annual net income of ALNY is -$440.24 M
What is the all time high annual net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual net profit is -$4.14 M
What is Alnylam Pharmaceuticals annual net income year-on-year change?
Over the past year, ALNY annual net profit has changed by +$690.91 M (+61.08%)
What is Alnylam Pharmaceuticals quarterly net profit?
The current quarterly net income of ALNY is -$111.57 M
What is the all time high quarterly net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly net profit is $147.75 M
What is Alnylam Pharmaceuticals quarterly net income year-on-year change?
Over the past year, ALNY quarterly net profit has changed by -$259.32 M (-175.51%)
What is Alnylam Pharmaceuticals TTM net profit?
The current TTM net income of ALNY is -$332.26 M
What is the all time high TTM net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM net profit is -$2.15 M
What is Alnylam Pharmaceuticals TTM net income year-on-year change?
Over the past year, ALNY TTM net profit has changed by +$177.60 M (+34.83%)